XTRA:WL6

Stock Analysis Report

Executive Summary

Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the United States, China, and Australia.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.

Share Price & News

How has Heidelberg Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.7%

WL6

1.0%

DE Biotechs

1.4%

DE Market


1 Year Return

-5.7%

WL6

1.3%

DE Biotechs

3.7%

DE Market

Return vs Industry: WL6 underperformed the German Biotechs industry which returned 1.3% over the past year.

Return vs Market: WL6 underperformed the German Market which returned 3.7% over the past year.


Shareholder returns

WL6IndustryMarket
7 Day-2.7%1.0%1.4%
30 Day-10.8%-5.5%1.3%
90 Day-22.1%-4.4%3.4%
1 Year-5.7%-5.7%1.5%1.3%7.0%3.7%
3 Year39.9%39.7%67.3%65.6%18.5%8.3%
5 Year-0.1%-0.2%12.9%10.4%42.2%22.9%

Price Volatility Vs. Market

How volatile is Heidelberg Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Heidelberg Pharma undervalued compared to its fair value and its price relative to the market?

2.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate WL6's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate WL6's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: WL6 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: WL6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate WL6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: WL6 is good value based on its PB Ratio (2.9x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Heidelberg Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

56.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: WL6 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: WL6 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: WL6 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: WL6's revenue (20.2% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: WL6's revenue (20.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if WL6's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Heidelberg Pharma performed over the past 5 years?

-20.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: WL6 is unprofitable, and losses have increased over the past 5 years at a rate of -20.3% per year.

Accelerating Growth: Unable to compare WL6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WL6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: WL6 has a negative Return on Equity (-48.12%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: WL6 is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: WL6 is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Heidelberg Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: WL6's short term assets (€14.6M) exceeds its short term liabilities (€5.3M)

Long Term Liabilities: WL6 has no long term liabilities


Debt to Equity History and Analysis

Debt Level: WL6 is debt free.

Reducing Debt: WL6 had no debt 5 years ago.


Balance Sheet

Inventory Level: WL6 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if WL6's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: WL6 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: WL6 has sufficient cash runway for 1.117553 years if free cash flow continues to reduce at historical rates of -18.8% each year.


Next Steps

Dividend

What is Heidelberg Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate WL6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate WL6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if WL6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if WL6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of WL6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Heidelberg Pharma's salary, the management and board of directors tenure and is there insider trading?

8.3yrs

Average board tenure


CEO

Jan Schmidt-Brand (61yo)

0yrs

Tenure

€313,104

Compensation

Dr. Jur. Jan Schmidt-Brand has been the Chief Financial Officer of Wilex AG since September 01, 2012 and serves as its Member of The Executive Management Board and Chief Executive Officer. Dr. Jur. Schmidt ...


CEO Compensation Analysis

Compensation vs. Market: Jan's total compensation ($USD348.78K) is about average for companies of similar size in the German market ($USD216.74K).

Compensation vs Earnings: Jan's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

8.3yrs

Average Tenure

52yo

Average Age

Experienced Board: WL6's board of directors are considered experienced (8.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jan Schmidt-Brand (61yo)

    CEO, CFO & Member of the Executive Management Board

    • Tenure: 0yrs
    • Compensation: €313.10k
  • Andreas Pahl

    Chief Scientific Officer

    • Tenure: 3.3yrs
    • Compensation: €285.58k
  • Sylvia Wimmer

    Manager of Corporate Communications

    • Tenure: 0yrs

Board Members

  • Friedrich von Bohlen und Halbach (57yo)

    Member of the Supervisory Board

    • Tenure: 14.4yrs
    • Compensation: €26.50k
  • Georg Baur

    Deputy Chairman of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: €41.75k
  • Christof Hettich

    Chairman of Supervisory Board

    • Tenure: 9.1yrs
    • Compensation: €52.50k
  • Birgit Kudlek (52yo)

    Member of the Supervisory Board

    • Tenure: 7.4yrs
    • Compensation: €26.50k
  • Mathias Hothum (52yo)

    Member of the Supervisory Board

    • Tenure: 4.3yrs
    • Compensation: €24.75k

Company Information

Heidelberg Pharma AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heidelberg Pharma AG
  • Ticker: WL6
  • Exchange: XTRA
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €60.540m
  • Shares outstanding: 28.16m
  • Website: https://heidelberg-pharma.com

Number of Employees


Location

  • Heidelberg Pharma AG
  • Schriesheimer Strasse 101
  • Ladenburg
  • Baden-Württemberg
  • 68526
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
WL6DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
WL6XTRA (XETRA Trading Platform)YesCommon StockDEEURNov 2006
0QW5LSE (London Stock Exchange)YesCommon StockGBEURNov 2006
WL6DBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURNov 2006

Biography

Heidelberg Pharma AG, through its subsidiaries, operates as a biopharmaceutical company that focuses on oncology and antibodies, and specializes in antibody drug conjugates (ADCs) in Germany, Europe, the U ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 21:02
End of Day Share Price2019/10/18 00:00
Earnings2019/08/31
Annual Earnings2018/11/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.